LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute)(LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute))

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用机制

免疫刺激剂

治疗领域

感染皮肤和肌肉骨骼疾病其他疾病

在研适应症-

非在研适应症

皮肤利什曼病黑热病后皮肤利什曼原虫

原研机构

Access To Advanced Health Institute

在研机构-

非在研机构

Access To Advanced Health Institute

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute) 相关的临床试验

NCT01011309 / Completed临床2期IIT

A Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine in the Treatment of Patients With Cutaneous Leishmaniasis

The purpose of this study is to determine the efficacy, safety, and immunogenicity of an investigational vaccine being developed for the treatment of leishmaniasis, including cutaneous leishmaniasis (CL). The vaccine, identified as LEISH-F2 + MPL-SE, consists of a Leishmania protein (LEISH-F2) together with an adjuvant MPL-SE.

开始日期2009-10-01

申办/合作机构

Access To Advanced Health Institute

NCT00982774 / Completed临床1期IIT

Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine in Combination With SSG in the Treatment of Patients With PKDL

A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of three injections of 10 µg LEISH-F2 + 25 µg MPL-SE given at 14-day intervals as an adjunct to standard chemotherapy with sodium stibogluconate (20 mg/kg/day for 40 days) in patients with PKDL.

开始日期2009-04-01

申办/合作机构

Access To Advanced Health Institute

100 项与 LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute) 相关的临床结果

登录后查看更多信息

100 项与 LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute) 相关的转化医学

登录后查看更多信息

100 项与 LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute) 相关的专利（医药）

登录后查看更多信息

100 项与 LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
皮肤利什曼病	临床2期	秘鲁	Access To Advanced Health Institute	2009-10-01
黑热病后皮肤利什曼原虫	临床1期	苏丹	Access To Advanced Health Institute	2009-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01011309 (CTgov)	临床2期	皮肤利什曼病	45	MPL-SE (Immunotherapy v1.4/1.5)	獵憲積憲壓蓋範襯壓膚(選願簾膚築憲糧夢鬱淵) = 鏇襯獵範遞膚選獵範艱鬱網艱餘糧選觸網獵網 (構齋齋艱範憲積範廠壓, 願夢襯鏇製鏇鏇鏇齋範 ~ 餘糧鹹窪顧獵觸衊範繭) 更多	-	2013-11-18
				MPL-SE (Immunotherapy v1.6)	獵憲積憲壓蓋範襯壓膚(選願簾膚築憲糧夢鬱淵) = 淵網築齋鑰蓋窪遞遞鑰鬱網艱餘糧選觸網獵網 (構齋齋艱範憲積範廠壓, 繭獵衊壓積襯衊艱淵鏇 ~ 淵積醖簾獵製積夢鑰網) 更多